186 related articles for article (PubMed ID: 26847287)
1. Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience.
Yue QF; Chen L; She XM; Hu B; Hu Y; Zou P; Liu XY
Yonsei Med J; 2016 Mar; 57(2):358-64. PubMed ID: 26847287
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes.
Saumell S; Florensa L; Luño E; Sanzo C; Cañizo C; Hernández JM; Cervera J; Gallart MA; Carbonell F; Collado R; Arenillas L; Pedro C; Bargay J; Nomdedeu B; Xicoy B; Vallespí T; Raya JM; Belloch L; Sanz GF; Solé F
Br J Haematol; 2012 Nov; 159(3):311-21. PubMed ID: 22958186
[TBL] [Abstract][Full Text] [Related]
3. Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study.
Qu S; Xu Z; Zhang Y; Qin T; Zhang T; Cui R; Xiao Z
Leuk Lymphoma; 2012 May; 53(5):940-6. PubMed ID: 22023524
[TBL] [Abstract][Full Text] [Related]
4. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
5. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
[TBL] [Abstract][Full Text] [Related]
6. [Establishment of Primary Adult MDS Nested Case-Control Study Cohort and Study of Risk Factors Associated with MDS Evolution to Leukemia].
Ma Y; Chen BB; Wang XQ; Xu XP; Lin GW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1638-46. PubMed ID: 26708886
[TBL] [Abstract][Full Text] [Related]
7. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
Wang SA; Jabbar K; Lu G; Chen SS; Galili N; Vega F; Jones D; Raza A; Kantarjian H; Garcia-Manero G; McDonnell TJ; Medeiros LJ
Leukemia; 2010 Apr; 24(4):740-7. PubMed ID: 20072149
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes.
Yan X; Wang L; Jiang L; Luo Y; Lin P; Yang W; Ren Y; Ma L; Zhou X; Mei C; Ye L; Xu G; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Med; 2021 Mar; 10(5):1759-1771. PubMed ID: 33609081
[TBL] [Abstract][Full Text] [Related]
9. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
Schanz J; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Tuechler H; Valent P; Hildebrandt B; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Kantarjian H; Germing U; Haase D; Estey E
J Clin Oncol; 2011 May; 29(15):1963-70. PubMed ID: 21519021
[TBL] [Abstract][Full Text] [Related]
10. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
11. Trisomy 8 is the most frequent cytogenetic abnormality in de novo myelodysplastic syndrome in China.
Xiao Y; Wei J; Chen Y; Zhang K; Zhou J; Zhang Y
Onkologie; 2012; 35(3):100-6. PubMed ID: 22414973
[TBL] [Abstract][Full Text] [Related]
12. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Quarna J; Lazzarino M; Bernasconi C
Leukemia; 2005 Aug; 19(8):1424-31. PubMed ID: 15920496
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.
Wang H; Wang X; Xu X; Lin G
Ann Hematol; 2010 Jun; 89(6):535-44. PubMed ID: 19921190
[TBL] [Abstract][Full Text] [Related]
14. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
Schanz J; Tüchler H; Solé F; Mallo M; Luño E; Cervera J; Granada I; Hildebrandt B; Slovak ML; Ohyashiki K; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Valent P; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Faderl S; Pierce S; Le Beau MM; Bennett JM; Greenberg P; Germing U; Haase D
J Clin Oncol; 2012 Mar; 30(8):820-9. PubMed ID: 22331955
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
16. MDS and AML with trisomy 8 as the sole chromosome aberration show different sex ratios and prognostic profiles: a study of 115 published cases.
Pedersen B
Am J Hematol; 1997 Dec; 56(4):224-9. PubMed ID: 9395183
[TBL] [Abstract][Full Text] [Related]
17. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
18. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
[TBL] [Abstract][Full Text] [Related]
20. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
